Clinical Trial Update: Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunomodulation with Escherichia coli Nissle 1917 in grass pollen rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Grass Pollen Rhinoconjunctivitis

Drugs mentioned

• Escherichia coli Nissle 1917 (Escherichia coli Nissle 1917)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Rhinoconjunctivitis | Phase 2 | Status: COMPLETED